Immunic, Inc. IMUX

US Biotechnology

$7.92 ▼ -0.50% ($-0.04)

📅 Earnings This Week

Open $7.89

Prev Close $7.96

Day Range $7.73 – $8.05

52W Range $5.06 – $17.43

Market Cap $108.61M

Beta 1.46

EPS (TTM) $-4.20

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2014-04-17
Shares Out.	13,640,000
Website	imux.com ↗
Phone	13026587581
Employees	95
Revenue	$0
Gross Profit	$0
Net Income	-$34.1M
Free Cash Flow	-$88.0M
Total Assets	$159.2M
Total Liabilities	$31.6M
Equity	$127.6M

About Immunic, Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Immunic, Inc. is a publicly traded company under the ticker symbol IMUX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.